This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Cytochrome P450 2B6.
Please shorten your article and try again.
Human | |
---|---|
Gene Name: | CYP2B6 |
Uniprot: | P20813 |
Entrez: | 1555 |
Belongs to: |
---|
cytochrome P450 family |
CPB6; CYP2B; CYP2B7; CYP2B7P; CYPIIB6cytochrome P450, subfamily IIB (phenobarbital-inducible); cytochrome P450 2B6; Cytochrome P450 IIB1; cytochrome P450, family 2, subfamily B; cytochrome P450, family 2, subfamily B, polypeptide 6; cytochrome P450, subfamily IIB (phenobarbital-inducible), polypeptide 6; EC 1.14.14.1; IIB1; P450
Mass (kDA):
56.278 kDA
Human | |
---|---|
Location: | 19q13.2 |
Sequence: | 19; NC_000019.10 (40991282..41018398) |
Expressed in liver, lung and heart right ventricle.
Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein.
Pharmacogenetic testing can be used to avoid the harmful effects of pharmaceuticals. This process has already had a positive impact in the lives of numerous people. It is now possible to utilize this information to develop a personalized medicine. This article will explore the different CYP2B6 variants. Let's look at two the most popular alleles. Which one should you select?
Many people have both HIV and HCV. It is essential to identify people with the same genotype, so that the correct treatment can be given. Patients suffering from both conditions require specific care and treatment since certain drugs may interact with each other. In addition, there is genetic variability among diverse ethnic groups, which makes it essential to take into consideration a patient's genotype before prescribing a specific drug.
An important regulator of the enzyme is the CYP2B6 genes. It is responsible for preventing HIV infection and has antiviral effects. Its use is restricted because of the high incidence of side effects like fever, Steven Johnson syndrome, and toxic epidermal necrolysis. The CYP2B6 gene and its variants have a significant effect on the patient's reaction to NVP.
This enzyme is essential to regulate the metabolism of different drugs. However the enzymes are varied, and their functions and structures differ greatly between individuals. Before making any clinical decisions, it is important to confirm any CYP2B6 markers. There are a variety of methods to determine the activity of CYP2B6 different cancers and in various kinds of tumors.
This enzyme can be found in all tissues. The CYP2B6*6 enzyme is less responsive to medications such as fludarabine or CP. It also is associated with decreased cytoreduction as well as CP toxicity. It can be used to identify patients suffering from chronic lymphocyticleukemia. These findings are important for the future development of new cancer treatments.
The CYP2B6 gene has a variety of variant alleles, including an allele containing two amino acids, K262R and Q172H. Depending on the ethnicityof the person, these variants can occur in between 15 and 60 percent of the population. These CYP2B6 variants are identified by their respective MAFs, which are the levels of MAF that determine the presence or absence of the variant. Boster Bio uses these data for diagnosis and to determine the predispositions of common cancers.
The CYP2B6 gene polymorphism can be studied using a reverse genetics method, which involves the identification of genetic variants in DNA as well as characterization of the genotyped livers and variant proteins. Several clinical studies have implicated that some allelic CYP2B6 variants are associated with lower expression of the liver, a higher efavirenz exposure, and increased risk of breast cancer. The combined effects of diverse CYP2B6 variants could be significant in determining the effectiveness of drugs and their side effects.
In contrast to other CYP2B6 inhibitors The variant gene found in the liver of a patient can be controlled by pharmacological means to decrease the concentration of drugs within the body. Drugs that reduce the expression levels of the mutant protein have the advantage of being safe and effective for both humans and animals. So, despite the limitations of our current technology, this technique could be utilized to overcome the disadvantages of CYP2B6 alleles.
There are two polymorphisms in CYP2B6 two of them are common and the other one rare. Both affect EFV oral clearance, and have different effects on PK. The first, CYP2B6*6 haplotype is associated with decreased EFV clearance and CNS adverse effects. The latter is less common however, it has been linked with plasma EFV exposure.
The second antibody in this series, the Boster Biologic CYP2B6*6 antibody , is extremely specific anti Cytochrome P450 2B6 antigen. The antibody is tested in WB and immunohistochemistry (IHC). The boster bio-CYP2B6*6 antibodies reacts with Human, Mouse and Rat proteins. This product has been confirmed for use in research.
The first polymorphism, CYP2B6*6, been discovered in the Boster Bio gene bank. Its gene number is 516G and the variant is referred to as CYP2B6*6. It was isolated from peripheral blood using Takara Bio's GenTLE DNA isolation kit. The Boster Bio CYP2B6*6 assay includes GenTLE DNA isolation kit and TaqMan Universal Master Mix II with UNG.
Boster Bio is a leading provider of immunology reagents , as well as in vitro drug metabolism reagents. Boster Bio provides reagents for the evaluation of potential drugs as inhibitors, substrates or inducers of enzymes responsible for drug metabolism. The company is a partner in manufacturing the reagent kit that is a proprietary one. The company's ELISA kits are extremely sensitive and its PICOKINE(tm) antibody kit gives excellent results.
We have identified the CYP2B6*4 variant in Boster Bio, and previously published data in a publicly accessible database. This analysis highlights how important it is to find the most frequent CYP2B6 allequence. These results are consistent with previous research involving numerous alleles and many people. We need additional data to fully understand the functional significance.
The allequence CYP2B6*4 consists of 37 star-alleles. Each one is linked to a distinct amino acid sequence. Furthermore, more than 30 amino acid-changing SNPs are known to influence gene expression including non-coding variants. Li et. al. Li and Li. published a report on the genetic variability of CYP2B6 sequences around the world. Table 1 lists the most common variants and their frequency.
Boster scientists collected the data in the database and used several methods to analyse the data. The methods used included PyroSequencing and an agarose gel metaphor of 4percent. PyroSequencing was used to identify homozygous null mutations. The results were analyzed using Taqman Real Time PCR on the Bio Rad platform.
Two amino acid modifications can be found in the CYP2B6*6 version, Q172H or K262R. This haplotype is prevalent in between 15 and 60 percent of the population. The variants are present in both the intron and promoter regions of the gene, and they have no effect on function. It is important to know that a person with the variants of this allele are at higher risk of developing several diseases.
In vitro studies have revealed that CYP2B6*6 alleles have different actions pharmacological. Moreover, efavirenz is more potent for people who have homozygous CYP2B6 alleles, which suggests that a reduction in dose prior to in homozygy could be beneficial. The results of these studies were not conclusive and further research is required.
The CYP2B6*6 allozyme has two amino acid mutations: Q172H and K262R. This allele occurs in fifteen to sixty percent of people dependent on the ethnicity. The variations within the promoter or intron of the gene, however, have little impact on the gene's functions. Boster Bio has conducted experiments using the CYP2B6*6 variant.
To determine the CYP2B6*6 allozyme's activity, the Qiagen EZ1 kit and a Qiagen BioRobot EZ1 workstation were used to extract genomic DNA from blood samples. The CYP2B6 primers were designed from the literature. The primers 785A, 1459C, and 1485A were taken from the intron regions of CYP2B6 and CYP2C19, respectively.
CYP2B6 is expressed in the liver. While its contribution to the total P450 pool is between 10 and 1 percent, it displays a wide variation between individuals between ten and hundred-fold. Although it was found in a small percentage of human liver samples during previous studies newer ones with improved antibodies showed that CYP2B6 is present in all human adult liver tissue.
CYP2B6*4 is an allele of a gene in the cytochrome P450 family. It is an increase in function mutation that may cause moderate effects dependent on substrate. This allele may disrupt the hydroxylation process in medications like propofol and clotiazepam. This allele was found to be absent in various populations, based on previous studies.
To determine the frequency of alleles we utilized the CYP2B6*4 genetic gene. The enzyme has two amino acid modifications (Q172H or K262R), and is found in between 15 and 60 percent of the population , based on the ethnicity. The variants are located in the intron and promoter regions of the gene which have no impact on the function.
We also studied the effects of polymorphisms within the CYP2B6*4 gene on its metabolism. Our study included a person who stopped taking efavirenz without guidance, yet she was able to detect levels 8 weeks after discontinuation of the drug. She was heterozygous for the G516T polymorphism and wild-type to the other CYP2B6 polymorphisms.
We also employed the polymorphism model to identify CYP2B6 responsible drugs. The majority of studies only provided the average profiles of a population or a single concentration at specific times. We employed four genetic variants from the literature and analyzed their effects on DGI. We also utilized bupropion and hydroxybupropion for predictors. We then adjusted for binding in the microsomal assay with Michaelis Menten constants.
PMID: 2573390 by Yamano S., et al. cDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver.
PMID: 2813061 by Miles J.S., et al. Alternative splicing in the human cytochrome P450IIB6 gene generates a high level of aberrant messages.